EUVIMEDEUVIMED entdecken
Studienprotokoll

Latent viral reactivation in non-transplant patients receiving immunosuppressive therapies: A call for a standardised protocol for CMV and EBV monitoring

Thomas Marandu

Tanzania Journal of Health Research · 03.03.2026 · 27 (1) · 3217-36

DOI: 10.4314/thrb.v27i1.17 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Tanzania Journal of Health Research, online erschienen am 03.03.2026. Verfasst von Thomas Marandu.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Human cytomegalovirus (CMV) and Epstein-Barr virus (EBV) are ubiquitous viruses in the population, particularly in lower- and middle-income countries, with a prevalence exceeding 90%. Protocols for managing the reactivation of these viruses in solid organ or bone marrow transplant recipients have been established. In contrast, management of CMV and EBV reactivation in non-transplant patients receiving drugs or treatments known to suppress host immunity has not been established and approved as a routine clinical practice. Methodology: Existing evidence on latent CMV or EBV reactivations in non-transplant patients undergoing various treatments that suppress their immune systems was gatherer and synthesised. Literature was retrieved from two primary databases, PubMed/MEDLINE and Google Scholar, using a combination of relevant keywords and Boolean operators.

Results

This narrative review highlights different studies that have shown how medications or treatments for some diseases, such as COVID-19, haematology, and solid cancers, can reactivate CMV and EBV, leading to increased morbidity or mortality. Possible mechanisms for viral reactivation induced by the medications or treatments are discussed. Most of the studies addressed include protocols for monitoring CMV and EBV viral load and treating viral reactivations to improve the primary disease outcomes.

Conclusion

Considering the endemic nature of these viruses in the population and the increased prevalence of triggering diseases discussed, the current review underscores a need for routine monitoring and management of symptomatic CMV and EBV reactivations in patients with a high risk of reactivation.

Zitieren

APA

Marandu, T. (2026). Latent viral reactivation in non-transplant patients receiving immunosuppressive therapies: A call for a standardised protocol for CMV and EBV monitoring. Tanzania Journal of Health Research, 27(1), 3217-36. https://doi.org/10.4314/thrb.v27i1.17

Vancouver

Marandu T. Latent viral reactivation in non-transplant patients receiving immunosuppressive therapies: A call for a standardised protocol for CMV and EBV monitoring. Tanzania Journal of Health Research. 2026;27(1):3217-36. doi:10.4314/thrb.v27i1.17

BibTeX
@article{Marandu2026,
  author = {Marandu, Thomas},
  title = {Latent viral reactivation in non-transplant patients receiving immunosuppressive therapies: A call for a standardised protocol for CMV and EBV monitoring},
  journal = {Tanzania Journal of Health Research},
  year = {2026},
  volume = {27},
  number = {1},
  pages = {3217--36},
  doi = {10.4314/thrb.v27i1.17}
}
Kostenlos starten →